My watch list  


Systematic (IUPAC) name
3-Bromo-N-[ [(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide
CAS number 117591-79-4
ATC code N05AL04
PubChem 54477
Chemical data
Formula  ?
Mol. mass 371.27 g/mol
Pharmacokinetic data
Bioavailability C16H23BrN2O3
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Remoxipride is a substituted benzamide which was a promising antipsychotic during clinical trials in the 1990s, but was removed due to possible side effects.

Clinical trials

Remoxipride is a selective D2 antagonist, with a relatively low effective dosage and low incidence of side effects relative to haloperidol. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Remoxipride". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE